Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRVB Provention Bio (PRVB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Provention Bio Stock (NASDAQ:PRVB) 30 days 90 days 365 days Advanced Chart Ad WealthPressCould TSLA reach $500 a share? Free ebook says it’s possible.Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Get Provention Bio alerts:Sign Up Key Stats Today's Range$24.98▼$25.0050-Day Range$23.74▼$24.9852-Week Range$3.18▼$25.00Volume9.12 million shsAverage Volume2.28 million shsMarket Capitalization$2.37 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Read More… Could TSLA reach $500 a share? Free ebook says it’s possible. (Ad)Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Receive PRVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PRVB Stock News HeadlinesMacrogenics Inc MGNXDecember 29, 2023 | morningstar.comSanofi/Provention: innovative diabetes drug is a good fitMay 1, 2023 | finance.yahoo.com2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.November 5, 2024 | Investing Daily (Ad)Those who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%April 29, 2023 | finance.yahoo.comSanofi completes Provention Bio acquisitionApril 28, 2023 | seekingalpha.comEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineApril 27, 2023 | finance.yahoo.comSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 27, 2023 | finanznachrichten.deProvention Bio gains after HSR waiting period for Sanofi deal expiredApril 26, 2023 | seekingalpha.comSee More Headlines PRVB Stock Analysis - Frequently Asked Questions How were Provention Bio's earnings last quarter? Provention Bio, Inc. (NASDAQ:PRVB) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The firm earned $0.68 million during the quarter, compared to analyst estimates of $3.75 million. Provention Bio had a negative trailing twelve-month return on equity of 103.36% and a negative net margin of 880.69%. What other stocks do shareholders of Provention Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Provention Bio investors own include NVIDIA (NVDA), NIO (NIO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Meta Platforms (META), VBI Vaccines (VBIV) and Amarin (AMRN). Company Calendar Last Earnings11/04/2021Today11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PRVB CUSIPN/A CIK1695357 Webwww.proventionbio.com Phone(908) 428-9136FaxN/AEmployees82Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,570,000.00 Net Margins-880.69% Pretax Margin-984.54% Return on Equity-103.36% Return on Assets-69.08% Debt Debt-to-Equity Ratio0.19 Current Ratio1.93 Quick Ratio1.92 Sales & Book Value Annual Sales$12.90 million Price / Sales183.54 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book17.84Miscellaneous Outstanding Shares94,780,000Free Float82,365,000Market Cap$2.37 billion OptionableNot Optionable Beta2.47 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:PRVB) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provention Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provention Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.